Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Supply, Demand and Key Producers, 2026-2032

June 2026 | 197 pages | ID: G66662146470EN
GlobalInfoResearch

Abstracts

The global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market size is expected to reach $ 9025 million by 2032, rising at a market growth of 11.4% CAGR during the forecast period (2026-2032).

Artificial substitutes for rare and endangered animal-derived medicinal materials refer to products developed through chemical synthesis or biotechnological approaches (including synthetic biology, bionics, cell engineering, etc.) that partially or fully replicate the efficacy of natural rare and endangered animal-derived medicinal materials (such as musk, bezoar, tiger bone, bear bile powder, antelope horn, pangolin scales, etc.), serving as raw material supplies for the production of Chinese patent medicines. These artificial substitutes are filed under Category 1.3 of the Chinese herbal medicine registration classification (“new medicinal materials and their preparations”) and are approved for market after pharmaceutical, pharmacological/toxicological, and clinical studies demonstrate comparability with natural materials. The core value lies in protecting wildlife resources while ensuring raw material supply security for well-established Chinese patent medicines (such as Angong Niuhuang Wan, Shexiang Baoxin Wan, Pien Tze Huang, etc.).

The artificial substitutes for rare and endangered animal-derived medicinal materials are transitioning from monopoly to a structure of intensified competition and regulatory bottlenecks. On pricing, new entrants in in vitro cultivated bezoar (Baiyunshan Caizhilin, Yunnan Pharmaceutical Group, Sichuan Shennong, etc.) have quoted below RMB 130,000/kg, putting pressure on former sole supplier Jianmin Dapeng’s pricing system; artificial musk remains exclusively priced by Beijing Lianxin with stable terminal prices; artificial tiger bone powder is exclusively supplied by Ginwa Enterprise with no price erosion. Gross margins diverge sharply: Jianmin Dapeng’s in vitro cultivated bezoar achieves over RMB 1.5 million net profit per ton, contributing 35%-40% of Jianmin Group’s gross margin, yet faces downward pressure as competition intensifies; Beijing Lianxin maintains high margins on its exclusive artificial musk license; Ginwa Enterprise’s artificial tiger bone powder enjoys stable margins due to classified formula and patent protection. Downstream applications are concentrated in emergency Chinese patent medicines (Angong Niuhuang Wan, Shexiang Baoxin Wan), chronic disease management (Pien Tze Huang, Jintiange Capsule), and over 300 classical formulas, with extremely rigid demand. Incremental demand comes from policy-driven substitution (NMPA’s 2025 announcement supporting substitutes for pangolin scales, antelope horn, bear bile powder, etc.) and resource scarcity-driven replacement. Upstream includes raw material supply (natural musk, natural bezoar, bear bile) and technology R&D (synthetic biology, biomimetic synthesis); downstream includes pharmaceutical manufacturers (Tongrentang, Guangyuyuan, Pien Tze Huang, etc.) and medical institutions. The landscape is tri-tiered: artificial musk (Beijing Lianxin monopoly, >99% substitution rate, saturated market); in vitro cultivated bezoar (moving from Jianmin Dapeng sole supplier to at least six competitors, capacity expansion 10-20x, initial price war); artificial tiger bone powder (Ginwa Enterprise exclusive, steady growth); bear bile/antelope horn/pangolin scales (regulatory bottleneck: Yanbian Bear Farm, Yunnan Dali Ruihe, etc. have filed supplementary applications; Chongqing Jize and Zhongshan Bailing have manufacturing capabilities but none yet approved; no legal entity holds production qualification for antelope horn or pangolin substitutes). Key uncertainties lie in approval timelines – despite CDE’s technical guidelines, actual approval dates, clinical equivalence validation standards, and conditional approval pathways remain unclear. Additionally, capacity release schedules and price war intensity will reshape value distribution in the cultivated bezoar segment. Conclusion: The artificial substitutes sector is driven by three forces – irreversible resource depletion, accelerating policy-mandated substitution, and mature technology pathways. The core characteristics are monopoly in mature categories (musk, tiger bone), intensifying competition in scaling categories (bezoar), and regulatory bottlenecks in blank categories (bear bile, antelope horn, pangolin). The greatest value variable is not technical feasibility but who gains approval first, under what standards, and how capacity and cost advantages translate into market share post-approval.

This report studies the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material total production and demand, 2021-2032, (Tons)
Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material total production value, 2021-2032, (USD Million)
Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Tons), (based on production site)
Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material consumption by region & country, CAGR, 2021-2032 & (Tons)
U.S. VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material domestic production, consumption, key domestic manufacturers and share
Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Tons)
Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material production by Type, production, value, CAGR, 2021-2032, (USD Million) & (Tons)
Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Tons)

This report profiles key players in the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Beijing Lianxin Pharmaceutical, Shandong Hongjitang Pharmaceutical, Firmenich, Givaudan, International Flavors & Fragrances (IFF), Symrise, Takasago International, Wuhan Jianmin Dapeng Pharmaceutical, HEC (HEC Pharma), Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Tons) and average price (US$/Ton) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market, By Region:

• United States
• China
• Europe
• Japan
• South Korea
• ASEAN
• India
• Rest of World

Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market, Segmentation by Type:

• Musk
• Bezoar
• Tiger Bone
• Bear Bile Powder
• Antelope Horn
• Pangolin Scales
• Others

Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market, Segmentation by Process:

• Chemical Synthesis
• Biosynthesis / Synthetic Biology
• In Vitro Cultivation
• Biomimetic / Bionic Synthesis
• Economic Animal Byproduct Synergistic Compatibility

Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market, Segmentation by Application:

• Acute Critical Care Chinese Patent Medicines
• Chronic Disease Management Chinese Patent Medicines
• Classical Prescriptions / Traditional Formulas
• Preparation Intermediates / APIs
• Others

Companies Profiled:

• Beijing Lianxin Pharmaceutical
• Shandong Hongjitang Pharmaceutical
• Firmenich
• Givaudan
• International Flavors & Fragrances (IFF)
• Symrise
• Takasago International
• Wuhan Jianmin Dapeng Pharmaceutical
• HEC (HEC Pharma)
• Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory)
• Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical)
• Yunnan Pharmaceutical Group
• Sichuan Shennong Pharmaceutical
• Jiangsu Binghetang Pharmaceutical
• Baicaotang Pharmaceutical
• Koyuan Pharmaceutical
• Zhongxing Mushroom (002772)
• Yichang Dongguang Winterworm Summerherb Ecological Breeding
• Xinshida Biotechnology
• Guangdong Rundongxia Health Industry
• SnowRong Bio (300511)
• Beijing Yanji Biotechnology
• Qinghai Digital Healing Intelligent Technology
• Monolis
• Chongqing Jize Biotechnology
• Zhongshan Bailing Biotechnology
• Yanbian Bear Farm
• Yunnan Tianyou Xiongye Pharmaceutical
• Yunnan Dali Ruihe Pharmaceutical
• Heilongjiang Yebao Pharmaceutical
• Tieling Shenxiong Pharmaceutical
• Guangzhou Jinxiong Pharmaceutical
• Lanzhou Fengchun Sheye Technology
• Xinjiang Baokang Pharmaceutical
• Hunan Huana Pharmaceutical (688799)
• Fujian Zhongyi Pharmaceutical
• Anhui Kebao Bioengineering
• Shaanxi Jichuang Huizhi Biotechnology
• BASF
• Soda Aromatic
• ACS International
• Triveni Chemicals
• Puyang Yuantai Fine Chemicals
• Chance Sun Import & Export
• Wanxiang Technology
• NHU
• Puyang Ouya Aromas
• Anhui Jinhe Industrial
• Jiayuan Fragrances
• Daewoong Chemical
• Mitsubishi Tanabe Pharma
• ICE Group
• PharmaZell
• Dipharma Francis
• Tsumura
• Kracie
• Tochimoto
• Itoh Kampo
• Kokando
• Ohmine

Key Questions Answered:
1. How big is the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market?
2. What is the demand of the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market?
3. What is the year over year growth of the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market?
4. What is the production and production value of the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market?
5. Who are the key producers in the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Introduction
1.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Supply & Forecast
  1.2.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value (2021 & 2025 & 2032)
  1.2.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2032)
  1.2.3 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Pricing Trends (2021-2032)
1.3 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Region (Based on Production Site)
  1.3.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Region (2021-2032)
  1.3.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Region (2021-2032)
  1.3.3 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Region (2021-2032)
  1.3.4 North America Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2032)
  1.3.5 Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2032)
  1.3.6 China Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2032)
  1.3.7 Japan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Major Market Trends

2 DEMAND SUMMARY

2.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Demand (2021-2032)
2.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption by Region
  2.2.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption by Region (2021-2026)
  2.2.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption Forecast by Region (2027-2032)
2.3 United States Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption (2021-2032)
2.4 China Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption (2021-2032)
2.5 Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption (2021-2032)
2.6 Japan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption (2021-2032)
2.7 South Korea Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption (2021-2032)
2.8 ASEAN Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption (2021-2032)
2.9 India Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption (2021-2032)

3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Manufacturer (2021-2026)
3.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Manufacturer (2021-2026)
3.3 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Manufacturer (2021-2026)
3.4 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
  3.5.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Industry Rank of Major Manufacturers
  3.5.2 Global Concentration Ratios (CR4) for Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material in 2025
  3.5.3 Global Concentration Ratios (CR8) for Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material in 2025
3.6 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market: Overall Company Footprint Analysis
  3.6.1 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market: Region Footprint
  3.6.2 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market: Company Product Type Footprint
  3.6.3 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market: Company Product Application Footprint
3.7 Competitive Environment
  3.7.1 Historical Structure of the Industry
  3.7.2 Barriers of Market Entry
  3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Comparison
  4.1.1 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Comparison (2021 & 2025 & 2032)
  4.1.2 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Comparison
  4.2.1 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Comparison (2021 & 2025 & 2032)
  4.2.2 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption Comparison
  4.3.1 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption Comparison (2021 & 2025 & 2032)
  4.3.2 United States VS China: Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers and Market Share, 2021-2026
  4.4.1 United States Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers, Headquarters and Production Site (States, Country)
  4.4.2 United States Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value (2021-2026)
  4.4.3 United States Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2026)
4.5 China Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers and Market Share
  4.5.1 China Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers, Headquarters and Production Site (Province, Country)
  4.5.2 China Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value (2021-2026)
  4.5.3 China Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2026)
4.6 Rest of World Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers and Market Share, 2021-2026
  4.6.1 Rest of World Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers, Headquarters and Production Site (State, Country)
  4.6.2 Rest of World Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value (2021-2026)
  4.6.3 Rest of World Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
  5.2.1 Musk
  5.2.2 Bezoar
  5.2.3 Tiger Bone
  5.2.4 Bear Bile Powder
  5.2.5 Antelope Horn
  5.2.6 Pangolin Scales
  5.2.7 Others
5.3 Market Segment by Type
  5.3.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Type (2021-2032)
  5.3.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Type (2021-2032)
  5.3.3 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Type (2021-2032)

6 MARKET ANALYSIS BY PROCESS

6.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market Size Overview by Process: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Process
  6.2.1 Chemical Synthesis
  6.2.2 Biosynthesis / Synthetic Biology
  6.2.3 In Vitro Cultivation
  6.2.4 Biomimetic / Bionic Synthesis
  6.2.5 Economic Animal Byproduct Synergistic Compatibility
6.3 Market Segment by Process
  6.3.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Process (2021-2032)
  6.3.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Process (2021-2032)
  6.3.3 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Process (2021-2032)

7 MARKET ANALYSIS BY APPLICATION

7.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market Size Overview by Application: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Application
  7.2.1 Acute Critical Care Chinese Patent Medicines
  7.2.2 Chronic Disease Management Chinese Patent Medicines
  7.2.3 Classical Prescriptions / Traditional Formulas
  7.2.4 Preparation Intermediates / APIs
  7.2.5 Others
7.3 Market Segment by Application
  7.3.1 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Application (2021-2032)
  7.3.2 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Application (2021-2032)
  7.3.3 World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Application (2021-2032)

8 COMPANY PROFILES

8.1 Beijing Lianxin Pharmaceutical
  8.1.1 Beijing Lianxin Pharmaceutical Details
  8.1.2 Beijing Lianxin Pharmaceutical Major Business
  8.1.3 Beijing Lianxin Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.1.4 Beijing Lianxin Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.1.5 Beijing Lianxin Pharmaceutical Recent Developments/Updates
  8.1.6 Beijing Lianxin Pharmaceutical Competitive Strengths & Weaknesses
8.2 Shandong Hongjitang Pharmaceutical
  8.2.1 Shandong Hongjitang Pharmaceutical Details
  8.2.2 Shandong Hongjitang Pharmaceutical Major Business
  8.2.3 Shandong Hongjitang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.2.4 Shandong Hongjitang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.2.5 Shandong Hongjitang Pharmaceutical Recent Developments/Updates
  8.2.6 Shandong Hongjitang Pharmaceutical Competitive Strengths & Weaknesses
8.3 Firmenich
  8.3.1 Firmenich Details
  8.3.2 Firmenich Major Business
  8.3.3 Firmenich Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.3.4 Firmenich Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.3.5 Firmenich Recent Developments/Updates
  8.3.6 Firmenich Competitive Strengths & Weaknesses
8.4 Givaudan
  8.4.1 Givaudan Details
  8.4.2 Givaudan Major Business
  8.4.3 Givaudan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.4.4 Givaudan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.4.5 Givaudan Recent Developments/Updates
  8.4.6 Givaudan Competitive Strengths & Weaknesses
8.5 International Flavors & Fragrances (IFF)
  8.5.1 International Flavors & Fragrances (IFF) Details
  8.5.2 International Flavors & Fragrances (IFF) Major Business
  8.5.3 International Flavors & Fragrances (IFF) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.5.4 International Flavors & Fragrances (IFF) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.5.5 International Flavors & Fragrances (IFF) Recent Developments/Updates
  8.5.6 International Flavors & Fragrances (IFF) Competitive Strengths & Weaknesses
8.6 Symrise
  8.6.1 Symrise Details
  8.6.2 Symrise Major Business
  8.6.3 Symrise Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.6.4 Symrise Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.6.5 Symrise Recent Developments/Updates
  8.6.6 Symrise Competitive Strengths & Weaknesses
8.7 Takasago International
  8.7.1 Takasago International Details
  8.7.2 Takasago International Major Business
  8.7.3 Takasago International Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.7.4 Takasago International Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.7.5 Takasago International Recent Developments/Updates
  8.7.6 Takasago International Competitive Strengths & Weaknesses
8.8 Wuhan Jianmin Dapeng Pharmaceutical
  8.8.1 Wuhan Jianmin Dapeng Pharmaceutical Details
  8.8.2 Wuhan Jianmin Dapeng Pharmaceutical Major Business
  8.8.3 Wuhan Jianmin Dapeng Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.8.4 Wuhan Jianmin Dapeng Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.8.5 Wuhan Jianmin Dapeng Pharmaceutical Recent Developments/Updates
  8.8.6 Wuhan Jianmin Dapeng Pharmaceutical Competitive Strengths & Weaknesses
8.9 HEC (HEC Pharma)
  8.9.1 HEC (HEC Pharma) Details
  8.9.2 HEC (HEC Pharma) Major Business
  8.9.3 HEC (HEC Pharma) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.9.4 HEC (HEC Pharma) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.9.5 HEC (HEC Pharma) Recent Developments/Updates
  8.9.6 HEC (HEC Pharma) Competitive Strengths & Weaknesses
8.10 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory)
  8.10.1 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Details
  8.10.2 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Major Business
  8.10.3 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.10.4 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.10.5 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Recent Developments/Updates
  8.10.6 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Competitive Strengths & Weaknesses
8.11 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical)
  8.11.1 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Details
  8.11.2 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Major Business
  8.11.3 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.11.4 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.11.5 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Recent Developments/Updates
  8.11.6 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Competitive Strengths & Weaknesses
8.12 Yunnan Pharmaceutical Group
  8.12.1 Yunnan Pharmaceutical Group Details
  8.12.2 Yunnan Pharmaceutical Group Major Business
  8.12.3 Yunnan Pharmaceutical Group Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.12.4 Yunnan Pharmaceutical Group Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.12.5 Yunnan Pharmaceutical Group Recent Developments/Updates
  8.12.6 Yunnan Pharmaceutical Group Competitive Strengths & Weaknesses
8.13 Sichuan Shennong Pharmaceutical
  8.13.1 Sichuan Shennong Pharmaceutical Details
  8.13.2 Sichuan Shennong Pharmaceutical Major Business
  8.13.3 Sichuan Shennong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.13.4 Sichuan Shennong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.13.5 Sichuan Shennong Pharmaceutical Recent Developments/Updates
  8.13.6 Sichuan Shennong Pharmaceutical Competitive Strengths & Weaknesses
8.14 Jiangsu Binghetang Pharmaceutical
  8.14.1 Jiangsu Binghetang Pharmaceutical Details
  8.14.2 Jiangsu Binghetang Pharmaceutical Major Business
  8.14.3 Jiangsu Binghetang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.14.4 Jiangsu Binghetang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.14.5 Jiangsu Binghetang Pharmaceutical Recent Developments/Updates
  8.14.6 Jiangsu Binghetang Pharmaceutical Competitive Strengths & Weaknesses
8.15 Baicaotang Pharmaceutical
  8.15.1 Baicaotang Pharmaceutical Details
  8.15.2 Baicaotang Pharmaceutical Major Business
  8.15.3 Baicaotang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.15.4 Baicaotang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.15.5 Baicaotang Pharmaceutical Recent Developments/Updates
  8.15.6 Baicaotang Pharmaceutical Competitive Strengths & Weaknesses
8.16 Koyuan Pharmaceutical
  8.16.1 Koyuan Pharmaceutical Details
  8.16.2 Koyuan Pharmaceutical Major Business
  8.16.3 Koyuan Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.16.4 Koyuan Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.16.5 Koyuan Pharmaceutical Recent Developments/Updates
  8.16.6 Koyuan Pharmaceutical Competitive Strengths & Weaknesses
8.17 Zhongxing Mushroom (002772)
  8.17.1 Zhongxing Mushroom (002772) Details
  8.17.2 Zhongxing Mushroom (002772) Major Business
  8.17.3 Zhongxing Mushroom (002772) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.17.4 Zhongxing Mushroom (002772) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.17.5 Zhongxing Mushroom (002772) Recent Developments/Updates
  8.17.6 Zhongxing Mushroom (002772) Competitive Strengths & Weaknesses
8.18 Yichang Dongguang Winterworm Summerherb Ecological Breeding
  8.18.1 Yichang Dongguang Winterworm Summerherb Ecological Breeding Details
  8.18.2 Yichang Dongguang Winterworm Summerherb Ecological Breeding Major Business
  8.18.3 Yichang Dongguang Winterworm Summerherb Ecological Breeding Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.18.4 Yichang Dongguang Winterworm Summerherb Ecological Breeding Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.18.5 Yichang Dongguang Winterworm Summerherb Ecological Breeding Recent Developments/Updates
  8.18.6 Yichang Dongguang Winterworm Summerherb Ecological Breeding Competitive Strengths & Weaknesses
8.19 Xinshida Biotechnology
  8.19.1 Xinshida Biotechnology Details
  8.19.2 Xinshida Biotechnology Major Business
  8.19.3 Xinshida Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.19.4 Xinshida Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.19.5 Xinshida Biotechnology Recent Developments/Updates
  8.19.6 Xinshida Biotechnology Competitive Strengths & Weaknesses
8.20 Guangdong Rundongxia Health Industry
  8.20.1 Guangdong Rundongxia Health Industry Details
  8.20.2 Guangdong Rundongxia Health Industry Major Business
  8.20.3 Guangdong Rundongxia Health Industry Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.20.4 Guangdong Rundongxia Health Industry Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.20.5 Guangdong Rundongxia Health Industry Recent Developments/Updates
  8.20.6 Guangdong Rundongxia Health Industry Competitive Strengths & Weaknesses
8.21 SnowRong Bio (300511)
  8.21.1 SnowRong Bio (300511) Details
  8.21.2 SnowRong Bio (300511) Major Business
  8.21.3 SnowRong Bio (300511) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.21.4 SnowRong Bio (300511) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.21.5 SnowRong Bio (300511) Recent Developments/Updates
  8.21.6 SnowRong Bio (300511) Competitive Strengths & Weaknesses
8.22 Beijing Yanji Biotechnology
  8.22.1 Beijing Yanji Biotechnology Details
  8.22.2 Beijing Yanji Biotechnology Major Business
  8.22.3 Beijing Yanji Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.22.4 Beijing Yanji Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.22.5 Beijing Yanji Biotechnology Recent Developments/Updates
  8.22.6 Beijing Yanji Biotechnology Competitive Strengths & Weaknesses
8.23 Qinghai Digital Healing Intelligent Technology
  8.23.1 Qinghai Digital Healing Intelligent Technology Details
  8.23.2 Qinghai Digital Healing Intelligent Technology Major Business
  8.23.3 Qinghai Digital Healing Intelligent Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.23.4 Qinghai Digital Healing Intelligent Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.23.5 Qinghai Digital Healing Intelligent Technology Recent Developments/Updates
  8.23.6 Qinghai Digital Healing Intelligent Technology Competitive Strengths & Weaknesses
8.24 Monolis
  8.24.1 Monolis Details
  8.24.2 Monolis Major Business
  8.24.3 Monolis Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.24.4 Monolis Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.24.5 Monolis Recent Developments/Updates
  8.24.6 Monolis Competitive Strengths & Weaknesses
8.25 Chongqing Jize Biotechnology
  8.25.1 Chongqing Jize Biotechnology Details
  8.25.2 Chongqing Jize Biotechnology Major Business
  8.25.3 Chongqing Jize Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.25.4 Chongqing Jize Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.25.5 Chongqing Jize Biotechnology Recent Developments/Updates
  8.25.6 Chongqing Jize Biotechnology Competitive Strengths & Weaknesses
8.26 Zhongshan Bailing Biotechnology
  8.26.1 Zhongshan Bailing Biotechnology Details
  8.26.2 Zhongshan Bailing Biotechnology Major Business
  8.26.3 Zhongshan Bailing Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.26.4 Zhongshan Bailing Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.26.5 Zhongshan Bailing Biotechnology Recent Developments/Updates
  8.26.6 Zhongshan Bailing Biotechnology Competitive Strengths & Weaknesses
8.27 Yanbian Bear Farm
  8.27.1 Yanbian Bear Farm Details
  8.27.2 Yanbian Bear Farm Major Business
  8.27.3 Yanbian Bear Farm Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.27.4 Yanbian Bear Farm Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.27.5 Yanbian Bear Farm Recent Developments/Updates
  8.27.6 Yanbian Bear Farm Competitive Strengths & Weaknesses
8.28 Yunnan Tianyou Xiongye Pharmaceutical
  8.28.1 Yunnan Tianyou Xiongye Pharmaceutical Details
  8.28.2 Yunnan Tianyou Xiongye Pharmaceutical Major Business
  8.28.3 Yunnan Tianyou Xiongye Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.28.4 Yunnan Tianyou Xiongye Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.28.5 Yunnan Tianyou Xiongye Pharmaceutical Recent Developments/Updates
  8.28.6 Yunnan Tianyou Xiongye Pharmaceutical Competitive Strengths & Weaknesses
8.29 Yunnan Dali Ruihe Pharmaceutical
  8.29.1 Yunnan Dali Ruihe Pharmaceutical Details
  8.29.2 Yunnan Dali Ruihe Pharmaceutical Major Business
  8.29.3 Yunnan Dali Ruihe Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
  8.29.4 Yunnan Dali Ruihe Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, Price, Value, Gross Margin and Market Share (2021-2026)
  8.29.5 Yunnan Dali Ruihe Pharmaceutical Recent Developments/Updates
  8.29.6 Yunnan Dali Ruihe Pharmaceutical Competitive Strengths & Weaknesses
8.30 Heilongjiang Yebao Pharmaceutical
8.31 Tieling Shenxiong Pharmaceutical
8.32 Guangzhou Jinxiong Pharmaceutical
8.33 Lanzhou Fengchun Sheye Technology
8.34 Xinjiang Baokang Pharmaceutical
8.35 Hunan Huana Pharmaceutical (688799)
8.36 Fujian Zhongyi Pharmaceutical
8.37 Anhui Kebao Bioengineering
8.38 Shaanxi Jichuang Huizhi Biotechnology

List Of Tables

LIST OF TABLES

Table 1. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Region (2021-2026) & (USD Million)
Table 3. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Region (2027-2032) & (USD Million)
Table 4. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Market Share by Region (2021-2026)
Table 5. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Market Share by Region (2027-2032)
Table 6. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Region (2021-2026) & (Tons)
Table 7. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Region (2027-2032) & (Tons)
Table 8. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Market Share by Region (2021-2026)
Table 9. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Market Share by Region (2027-2032)
Table 10. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Region (2021-2026) & (US$/Ton)
Table 11. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Region (2027-2032) & (US$/Ton)
Table 12. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Major Market Trends
Table 13. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Tons)
Table 14. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption by Region (2021-2026) & (Tons)
Table 15. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption Forecast by Region (2027-2032) & (Tons)
Table 16. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Producers in 2025
Table 18. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Manufacturer (2021-2026) & (Tons)
Table 19. Production Market Share of Key Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Producers in 2025
Table 20. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Manufacturer (2021-2026) & (US$/Ton)
Table 21. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Company Evaluation Quadrant
Table 22. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Site of Key Manufacturer
Table 24. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market: Company Product Type Footprint
Table 25. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market: Company Product Application Footprint
Table 26. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Competitive Factors
Table 27. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material New Entrant and Capacity Expansion Plans
Table 28. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Mergers & Acquisitions Activity
Table 29. United States VS China Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Comparison, (2021 & 2025 & 2032) & (Tons)
Table 31. United States VS China Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Consumption Comparison, (2021 & 2025 & 2032) & (Tons)
Table 32. United States Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (2021-2026) & (Tons)
Table 36. United States Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Market Share (2021-2026)
Table 37. China Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, (2021-2026) & (Tons)
Table 41. China Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Market Share (2021-2026)
Table 42. Rest of World Based Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production, (2021-2026) & (Tons)
Table 46. Rest of World Based Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Market Share (2021-2026)
Table 47. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Type (2021-2026) & (Tons)
Table 49. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Type (2027-2032) & (Tons)
Table 50. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Type (2021-2026) & (USD Million)
Table 51. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Type (2027-2032) & (USD Million)
Table 52. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Type (2021-2026) & (US$/Ton)
Table 53. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Type (2027-2032) & (US$/Ton)
Table 54. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Process, (USD Million), 2021 & 2025 & 2032
Table 55. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Process (2021-2026) & (Tons)
Table 56. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Process (2027-2032) & (Tons)
Table 57. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Process (2021-2026) & (USD Million)
Table 58. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Process (2027-2032) & (USD Million)
Table 59. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Process (2021-2026) & (US$/Ton)
Table 60. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Process (2027-2032) & (US$/Ton)
Table 61. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 62. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Application (2021-2026) & (Tons)
Table 63. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production by Application (2027-2032) & (Tons)
Table 64. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Application (2021-2026) & (USD Million)
Table 65. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production Value by Application (2027-2032) & (USD Million)
Table 66. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Application (2021-2026) & (US$/Ton)
Table 67. World Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Average Price by Application (2027-2032) & (US$/Ton)
Table 68. Beijing Lianxin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 69. Beijing Lianxin Pharmaceutical Major Business
Table 70. Beijing Lianxin Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 71. Beijing Lianxin Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 72. Beijing Lianxin Pharmaceutical Recent Developments/Updates
Table 73. Beijing Lianxin Pharmaceutical Competitive Strengths & Weaknesses
Table 74. Shandong Hongjitang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 75. Shandong Hongjitang Pharmaceutical Major Business
Table 76. Shandong Hongjitang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 77. Shandong Hongjitang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Shandong Hongjitang Pharmaceutical Recent Developments/Updates
Table 79. Shandong Hongjitang Pharmaceutical Competitive Strengths & Weaknesses
Table 80. Firmenich Basic Information, Manufacturing Base and Competitors
Table 81. Firmenich Major Business
Table 82. Firmenich Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 83. Firmenich Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. Firmenich Recent Developments/Updates
Table 85. Firmenich Competitive Strengths & Weaknesses
Table 86. Givaudan Basic Information, Manufacturing Base and Competitors
Table 87. Givaudan Major Business
Table 88. Givaudan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 89. Givaudan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Givaudan Recent Developments/Updates
Table 91. Givaudan Competitive Strengths & Weaknesses
Table 92. International Flavors & Fragrances (IFF) Basic Information, Manufacturing Base and Competitors
Table 93. International Flavors & Fragrances (IFF) Major Business
Table 94. International Flavors & Fragrances (IFF) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 95. International Flavors & Fragrances (IFF) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 96. International Flavors & Fragrances (IFF) Recent Developments/Updates
Table 97. International Flavors & Fragrances (IFF) Competitive Strengths & Weaknesses
Table 98. Symrise Basic Information, Manufacturing Base and Competitors
Table 99. Symrise Major Business
Table 100. Symrise Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 101. Symrise Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 102. Symrise Recent Developments/Updates
Table 103. Symrise Competitive Strengths & Weaknesses
Table 104. Takasago International Basic Information, Manufacturing Base and Competitors
Table 105. Takasago International Major Business
Table 106. Takasago International Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 107. Takasago International Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 108. Takasago International Recent Developments/Updates
Table 109. Takasago International Competitive Strengths & Weaknesses
Table 110. Wuhan Jianmin Dapeng Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 111. Wuhan Jianmin Dapeng Pharmaceutical Major Business
Table 112. Wuhan Jianmin Dapeng Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 113. Wuhan Jianmin Dapeng Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 114. Wuhan Jianmin Dapeng Pharmaceutical Recent Developments/Updates
Table 115. Wuhan Jianmin Dapeng Pharmaceutical Competitive Strengths & Weaknesses
Table 116. HEC (HEC Pharma) Basic Information, Manufacturing Base and Competitors
Table 117. HEC (HEC Pharma) Major Business
Table 118. HEC (HEC Pharma) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 119. HEC (HEC Pharma) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 120. HEC (HEC Pharma) Recent Developments/Updates
Table 121. HEC (HEC Pharma) Competitive Strengths & Weaknesses
Table 122. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Basic Information, Manufacturing Base and Competitors
Table 123. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Major Business
Table 124. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 125. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 126. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Recent Developments/Updates
Table 127. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Competitive Strengths & Weaknesses
Table 128. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Basic Information, Manufacturing Base and Competitors
Table 129. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Major Business
Table 130. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 131. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 132. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Recent Developments/Updates
Table 133. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Competitive Strengths & Weaknesses
Table 134. Yunnan Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 135. Yunnan Pharmaceutical Group Major Business
Table 136. Yunnan Pharmaceutical Group Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 137. Yunnan Pharmaceutical Group Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 138. Yunnan Pharmaceutical Group Recent Developments/Updates
Table 139. Yunnan Pharmaceutical Group Competitive Strengths & Weaknesses
Table 140. Sichuan Shennong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 141. Sichuan Shennong Pharmaceutical Major Business
Table 142. Sichuan Shennong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 143. Sichuan Shennong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 144. Sichuan Shennong Pharmaceutical Recent Developments/Updates
Table 145. Sichuan Shennong Pharmaceutical Competitive Strengths & Weaknesses
Table 146. Jiangsu Binghetang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 147. Jiangsu Binghetang Pharmaceutical Major Business
Table 148. Jiangsu Binghetang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 149. Jiangsu Binghetang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 150. Jiangsu Binghetang Pharmaceutical Recent Developments/Updates
Table 151. Jiangsu Binghetang Pharmaceutical Competitive Strengths & Weaknesses
Table 152. Baicaotang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 153. Baicaotang Pharmaceutical Major Business
Table 154. Baicaotang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 155. Baicaotang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 156. Baicaotang Pharmaceutical Recent Developments/Updates
Table 157. Baicaotang Pharmaceutical Competitive Strengths & Weaknesses
Table 158. Koyuan Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 159. Koyuan Pharmaceutical Major Business
Table 160. Koyuan Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 161. Koyuan Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 162. Koyuan Pharmaceutical Recent Developments/Updates
Table 163. Koyuan Pharmaceutical Competitive Strengths & Weaknesses
Table 164. Zhongxing Mushroom (002772) Basic Information, Manufacturing Base and Competitors
Table 165. Zhongxing Mushroom (002772) Major Business
Table 166. Zhongxing Mushroom (002772) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 167. Zhongxing Mushroom (002772) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 168. Zhongxing Mushroom (002772) Recent Developments/Updates
Table 169. Zhongxing Mushroom (002772) Competitive Strengths & Weaknesses
Table 170. Yichang Dongguang Winterworm Summerherb Ecological Breeding Basic Information, Manufacturing Base and Competitors
Table 171. Yichang Dongguang Winterworm Summerherb Ecological Breeding Major Business
Table 172. Yichang Dongguang Winterworm Summerherb Ecological Breeding Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 173. Yichang Dongguang Winterworm Summerherb Ecological Breeding Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 174. Yichang Dongguang Winterworm Summerherb Ecological Breeding Recent Developments/Updates
Table 175. Yichang Dongguang Winterworm Summerherb Ecological Breeding Competitive Strengths & Weaknesses
Table 176. Xinshida Biotechnology Basic Information, Manufacturing Base and Competitors
Table 177. Xinshida Biotechnology Major Business
Table 178. Xinshida Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 179. Xinshida Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 180. Xinshida Biotechnology Recent Developments/Updates
Table 181. Xinshida Biotechnology Competitive Strengths & Weaknesses
Table 182. Guangdong Rundongxia Health Industry Basic Information, Manufacturing Base and Competitors
Table 183. Guangdong Rundongxia Health Industry Major Business
Table 184. Guangdong Rundongxia Health Industry Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 185. Guangdong Rundongxia Health Industry Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 186. Guangdong Rundongxia Health Industry Recent Developments/Updates
Table 187. Guangdong Rundongxia Health Industry Competitive Strengths & Weaknesses
Table 188. SnowRong Bio (300511) Basic Information, Manufacturing Base and Competitors
Table 189. SnowRong Bio (300511) Major Business
Table 190. SnowRong Bio (300511) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 191. SnowRong Bio (300511) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 192. SnowRong Bio (300511) Recent Developments/Updates
Table 193. SnowRong Bio (300511) Competitive Strengths & Weaknesses
Table 194. Beijing Yanji Biotechnology Basic Information, Manufacturing Base and Competitors
Table 195. Beijing Yanji Biotechnology Major Business
Table 196. Beijing Yanji Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 197. Beijing Yanji Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 198. Beijing Yanji Biotechnology Recent Developments/Updates
Table 199. Beijing Yanji Biotechnology Competitive Strengths & Weaknesses
Table 200. Qinghai Digital Healing Intelligent Technology Basic Information, Manufacturing Base and Competitors
Table 201. Qinghai Digital Healing Intelligent Technology Major Business
Table 202. Qinghai Digital Healing Intelligent Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 203. Qinghai Digital Healing Intelligent Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 204. Qinghai Digital Healing Intelligent Technology Recent Developments/Updates
Table 205. Qinghai Digital Healing Intelligent Technology Competitive Strengths & Weaknesses
Table 206. Monolis Basic Information, Manufacturing Base and Competitors
Table 207. Monolis Major Business
Table 208. Monolis Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 209. Monolis Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 210. Monolis Recent Developments/Updates
Table 211. Monolis Competitive Strengths & Weaknesses
Table 212. Chongqing Jize Biotechnology Basic Information, Manufacturing Base and Competitors
Table 213. Chongqing Jize Biotechnology Major Business
Table 214. Chongqing Jize Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 215. Chongqing Jize Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 216. Chongqing Jize Biotechnology Recent Developments/Updates
Table 217. Chongqing Jize Biotechnology Competitive Strengths & Weaknesses
Table 218. Zhongshan Bailing Biotechnology Basic Information, Manufacturing Base and Competitors
Table 219. Zhongshan Bailing Biotechnology Major Business
Table 220. Zhongshan Bailing Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 221. Zhongshan Bailing Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 222. Zhongshan Bailing Biotechnology Recent Developments/Updates
Table 223. Zhongshan Bailing Biotechnology Competitive Strengths & Weaknesses
Table 224. Yanbian Bear Farm Basic Information, Manufacturing Base and Competitors
Table 225. Yanbian Bear Farm Major Business
Table 226. Yanbian Bear Farm Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 227. Yanbian Bear Farm Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 228. Yanbian Bear Farm Recent Developments/Updates
Table 229. Yanbian Bear Farm Competitive Strengths & Weaknesses
Table 230. Yunnan Tianyou Xiongye Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 231. Yunnan Tianyou Xiongye Pharmaceutical Major Business
Table 232. Yunnan Tianyou Xiongye Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 233. Yunnan Tianyou Xiongye Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 234. Yunnan Tianyou Xiongye Pharmaceutical Recent Developments/Updates
Table 235. Yunnan Tianyou Xiongye Pharmaceutical Competitive Strengths & Weaknesses
Table 236. Yunnan Dali Ruihe Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 237. Yunnan Dali Ruihe Pharmaceutical Major Business
Table 238. Yunnan Dali Ruihe Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 239. Yunnan Dali Ruihe Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 240. Yunnan Dali Ruihe Pharmaceutical Recent Developments/Updates
Table 241. Yunnan Dali Ruihe Pharmaceutical Competitive Strengths & Weaknesses
Table 242. Heilongjiang Yebao Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 243. Heilongjiang Yebao Pharmaceutical Major Business
Table 244. Heilongjiang Yebao Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 245. Heilongjiang Yebao Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 246. Heilongjiang Yebao Pharmaceutical Recent Developments/Updates
Table 247. Heilongjiang Yebao Pharmaceutical Competitive Strengths & Weaknesses
Table 248. Tieling Shenxiong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 249. Tieling Shenxiong Pharmaceutical Major Business
Table 250. Tieling Shenxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 251. Tieling Shenxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 252. Tieling Shenxiong Pharmaceutical Recent Developments/Updates
Table 253. Tieling Shenxiong Pharmaceutical Competitive Strengths & Weaknesses
Table 254. Guangzhou Jinxiong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 255. Guangzhou Jinxiong Pharmaceutical Major Business
Table 256. Guangzhou Jinxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 257. Guangzhou Jinxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 258. Guangzhou Jinxiong Pharmaceutical Recent Developments/Updates
Table 259. Guangzhou Jinxiong Pharmaceutical Competitive Strengths & Weaknesses
Table 260. Lanzhou Fengchun Sheye Technology Basic Information, Manufacturing Base and Competitors
Table 261. Lanzhou Fengchun Sheye Technology Major Business
Table 262. Lanzhou Fengchun Sheye Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services
Table 263. Lanzhou Fengchun Sheye Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Production (Tons), Price (US$/Ton), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 264. Lanzhou Fengchun Sheye Technology Recent Developments/Updates
Table 265. Lanzhou Fengchun Sheye Technology Competitive Strengths & Weaknesses
Table 266. Xinjiang Baokang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 267. Xinjiang Baokang Pharmaceutical Major Business
Table 268. Xinjiang Baokang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product and Services